| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $28.7M | — | -22.8% |
| SG&A Expense | $11.5M | — | -0.2% |
| Operating Income | -$48.6M | — | +4.0% |
| Net Income | -$47.2M | — | +4.4% |
| EPS (Basic) | -$0.17 | — | +19.0% |
| EPS (Diluted) | -$0.17 | — | +19.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $83.8M | +16.6% | -12.8% |
| Short-term Investments | $17.3M | -73.9% | +102.3% |
| Current Assets | $111.7M | -24.9% | -0.9% |
| Total Assets | $373.6M | -10.4% | -16.1% |
| Current Liabilities | $86.3M | +9.6% | +160.2% |
| Total Liabilities | $254.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$37.4M | — | +23.2% |
| Capital Expenditures | $288K | — | +111.8% |
| Investing Cash Flow | $49.4M | — | +197.8% |
| Financing Cash Flow | -$128K | — | -113.0% |
| Free Cash Flow | -$37.7M | — | +22.8% |
| +7.6% |
| Stockholders' Equity | $119.2M | -25.9% | -43.0% |